GRI Bio Secures $6.5M in January 2026, Extends Cash Runway to Q1 2027
Event summary
- GRI Bio reported $8.2M in cash and cash equivalents as of December 31, 2025, and raised an additional $6.5M in January 2026.
- The company's balance sheet is now strengthened to fund operations into Q1 2027.
- Positive Phase 2a clinical data for GRI-0621 in idiopathic pulmonary fibrosis reinforced clinical proof-of-concept.
- GRI-0803 is advancing through IND-enabling activities for autoimmune indications.
- Net loss for 2025 was $12M, with R&D expenses increasing by $3M due to GRI-0621 development.
The big picture
GRI Bio's recent funding and positive clinical data position it favorably in the competitive landscape of inflammatory and fibrotic disease treatments. The company's focus on NKT cell modulation aligns with broader industry trends toward targeted immune therapies. The extended cash runway provides a buffer for continued clinical development, but the need for additional funding may arise as larger Phase 2b trials approach.
What we're watching
- Clinical Validation
- How the Phase 2a data for GRI-0621 will translate into further clinical validation and regulatory approval.
- Funding Strategy
- Whether GRI Bio can sustain its current cash runway into 2027 and secure additional funding if needed.
- Pipeline Progression
- The pace at which GRI-0803 advances through IND-enabling studies and into clinical trials.
Related topics